Where is CVRx located?

CVRx is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota.

How many employees does CVRx have?

As of Sep 30, 2026, the latest employee count at CVRx is 258.

Is CVRx a funded company?

CVRx is a funded company, having raised a total of $394M across 10 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of CVRx?

CVRx's latest funding was a $***** Series F round on Jul 07, 2020, with participation from 8 investors.

Where does CVRx rank among its competitors?

CVRx ranks 1st amongst 99 active competitors, of which 58 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Berlin Heals, which secured $10M in Feb, 2026.

Who are the top competitors of CVRx?

CVRx's top competitors include Impulse Dynamics, CorWave and Element Science. Among them, Berlin Heals secured the most recent funding round in February, 2026.

CVRx - 2026 Company Profile, Team, Funding, Competitors & Financials

CVRx is a public company based in Minneapolis (United States), founded in 2001 by Robert Kieval. It operates as a Developer of implantable technology for hypertension and heart failure. CVRx has raised $394M in funding from investors like Johnson & Johnson Innovation – JJDC, New Enterprise Associates and Thomas Weisel Partners. The company has 99 active competitors, including 58 funded and 13 that have exited. Its top competitors include companies like Impulse Dynamics, CorWave and Element Science.

Company Details

CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the body's cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.

Website: cvrx.com
Social
Registered Address: Minneapolis, Minnesota

Key Metrics

Founded Year

2001

Location

Minneapolis, United States

Stage

Public

Total Funding

$394M in 10 rounds

Latest Funding Round

Series F, Jul 07, 2020, $*****

Investors

Johnson & Johnson Innovation – JJDC & 21 more

Ranked

1^st among 99 active competitors

Employee Count

258 as on Sep 30, 2026

Similar Companies

Impulse Dynamics & 125 more

Exit Details

Public

View CVRx's full profile

CVRx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
CVRX, INC. CIN: 411983744 , United States, Active	Dec 31, 2000	-	194 (As on Dec 31, 2024)	-

CVRx got listed on Jun 30, 2021.

Click here to take a look at CVRx's IPO in detail

CVRx has raised a total funding of $394M over 10 rounds. Its latest funding round was a Series F round on Jul 07, 2020 for $*****. 8 investors participated in its latest round. CVRx has 22 institutional investors.

Here is the list of recent funding rounds of CVRx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 07, 2020	6604407	Series F	7872739	5816598	8585719	5260366
May 31, 2019	6757037	Series F	4078825	8781492	2484652	New Enterprise Associates & 4 more
Aug 09, 2016	8664070	Conventional Debt	6825595	3237657	7739372	Oxford Finance

Access funding benchmarks and valuations. Sign up today!

View details of CVRx's funding rounds and investors

The founders of CVRx is Robert Kieval.

Here are the details of CVRx's key team members:

Robert Kieval: Former Founder of CVRx.

View details of CVRx's Founder profiles and Board Members

CVRx's employee count trend

CVRx has 258 employees as of Sep 26. Here is CVRx's employee count trend over the years:

Uncover CVRx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CVRx include Impulse Dynamics, CorWave and Element Science. Here is the list of Top 10 competitors of CVRx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CVRx 2001, Minneapolis (United States), Public	Developer of implantable technology for hypertension and heart failure	$394M	Gilde Healthcare, Piper Jaffray & 20 others	67/100
2nd	Impulse Dynamics 1998, Marlton (United States), Series F	Provider of implantable device for treatment of chronic heart failure	$685M	Perceptive Advisors, Redmile Group & 16 others	64/100
3rd	CorWave 2011, Paris (France), Series C	Developer of implantable blood pumps for the treatment of heart failure	$127M	Novo Holdings, Exor Ventures & 11 others	61/100
4th	Element Science 2013, San Francisco (United States), Series C	Wearable therapeutic device for treating sudden cardiac arrest	$193M	Deerfield, Qiming & 4 others	61/100
5th	SynCardia 2001, Tucson (United States), Public	Artificial heart	$72M	Athyrium Capital Management, SWK Holdings ... & 5 others	60/100
6th	Restore Medical 2016, Tel Aviv (Israel), Series B	Catheter-delivered implant for treatment of congestive heart failure	$32M	European Innovation Council, Pitango & 3 others	57/100
7th	FineHeart 2010, Pessac (France), Series C	Developer of an implantable cardiovascular device for treating heart failures	$51.9M	Verve Ventures, Broadview Ventures & 16 others	57/100
8th	Reprieve Cardiovascular 2018, Milford (United States), Series B	Developer of decongestion management solution for acute decompensated heart failure patients	$150M	Deerfield, Arboretum Ventures & 8 others	55/100
9th	Procyrion 2005, Houston (United States), Series E	Developing percutaneous mechanical circulatory support for heart failure and cardiorenal syndrome	$114M	Fannin Innovation Studio, Scientific Health Development ... & 4 others	54/100
10th	Berlin Heals 2010, Zug (Switzerland), Series B	Developer of a microcurrent device for heart failure treatment. This device is a novel cardiac implant that provides a minimal electrical direct current to the heart, promoting reverse remodeling of cardiac muscle tissue. The treatment has shown rapid improvements in heart function, size, and quality of life in clinical studies. The device is easily implantable and requires no additional medication or follow-up procedures. The company is currently conducting clinical studies to obtain regulatory approvals.	$34.6M	BLR Partners	51/100